ArticleBreast cancer (Dove Medical Press)2025
Safety Profile and Predictors of Adverse Events of Incadronate Disodium in Treating Breast Cancer Patients with Bone Metastases: A Retrospective Study.
Article in Breast cancer (Dove Medical Press), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Bone metastasis is a common complication in advanced breast cancer. Bisphosphonates like incadronate disodium have shown potential in reducing bone resorption and skeletal-related events. We therefore performed a retrospective study to evaluate the safety profile of incadronate disodium in breast cancer patients with bone metastases. Patients and Methods: This retrospective study was conducted involving 84 breast cancer patients with bone metastases who received incadronate disodium treatment between February 2022 and August 2024 in our center. The primary endpoint was the incidence of dental-related issues and acute phase reactions, with an analysis of the associated risk factors. The secondary endpoint was the incidence of other adverse events. Adverse events were recorded during treatment and within 90 days post-treatment. Results: Dental-related issues were observed in 33.3% of patients and only one (1.2%) developed medication-related osteonecrosis of the jaw. Higher risk was significantly associated with prolonged treatment duration (OR = 4.33, 95% CI:1.21-15.50), secondary bone metastases (OR = 6.3, 95% CI:1.58-25.00), and lower hemoglobin levels (OR = 4.16, 95% CI:1.31-13.2) at multivariate analysis. 26.2% patients occurred acute phase reactions. Higher medication doses (OR = 1.41, 95% CI:1.07-2.05), multiple metastatic sites (OR = 4.22, 95% CI:1.39-15.89) and lower hemoglobin levels (OR = 3.27, 95% CI:1.21-9.22) were significant in univariate analysis, but not in multivariate analysis. Rare adverse effects included renal dysfunction (1.2%) and hypocalcemia (4.76%). Conclusion: Incadronate disodium demonstrates a favorable safety profile for treating bone metastases in breast cancer patients. Identified risk factors, such as prolonged treatment duration and lower hemoglobin levels, highlight the need for intensified dental health management and personalized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.